Comprehensive medication guide to Caverject including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0–$50 copay for alprostadil injection when prior authorization is approved; most major plans require documented failure of oral PDE5 inhibitors. Medicare Part B may cover injectable alprostadil. Quantity limits and annual PA renewal typically apply.
Estimated Cash Pricing
$860–$1,058 retail for 6 vials of Caverject 40 mcg (brand, discontinued); Caverject Impulse was $288–$308 for 2 syringes. Generic alprostadil injection is now available and may cost significantly less. GoodRx coupons reduced Caverject Impulse to ~$222 per 2-pack.
Medfinder Findability Score
55/100
Summarize with AI
On this page
Caverject is a brand name for alprostadil, a synthetic form of Prostaglandin E1 (PGE1) that is injected directly into the corpus cavernosum of the penis to produce an erection. It has been FDA-approved for the treatment of erectile dysfunction (ED) since 1981, making it one of the longest-established injectable ED therapies available. Alprostadil is the only FDA-approved intracavernosal injection for erectile dysfunction.
Caverject is primarily prescribed for men with ED who have not responded adequately to oral PDE5 inhibitors (such as sildenafil or tadalafil), and for men with neurogenic ED following prostate surgery. In clinical studies, over 80% of men achieved an erection sufficient for sexual intercourse with Caverject. The medication produces an erection within 5–20 minutes and lasts up to 60 minutes on average.
Caverject brand was manufactured by Pfizer (Pharmacia & Upjohn Company LLC) in single-dose vials of 20 mcg and 40 mcg and as a prefilled dual-chamber syringe (Caverject Impulse) in 10 mcg and 20 mcg strengths. In July 2025, Pfizer discontinued the Caverject brand and released generic equivalents. Generic alprostadil injection and Edex (by Endo) are now the primary commercial sources.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Alprostadil is a Prostaglandin E1 (PGE1) agonist. When injected into the corpus cavernosum, it binds to prostaglandin E receptors (EP2 and EP3) on smooth muscle cells, activating adenylate cyclase and increasing intracellular cyclic AMP (cAMP). The elevation of cAMP causes smooth muscle relaxation in the corpus cavernosum and cavernosal arteries, significantly increasing blood flow into the penis.
Unlike oral PDE5 inhibitors (Viagra, Cialis) which amplify the natural arousal-induced nitric oxide/cGMP pathway, alprostadil works through an independent pathway and does not require sexual stimulation to produce an erection. This makes it particularly effective for men with neurogenic or severe vascular ED where the nitric oxide pathway is compromised.
After injection, alprostadil is metabolized primarily locally within the penile tissue. Approximately 80% of any drug that enters systemic circulation is cleared in a single pass through the lungs. This limits systemic exposure and explains why serious systemic side effects are relatively uncommon with intracavernosal alprostadil.
2.5 mcg — injection
Starting dose for vasculogenic/psychogenic/mixed ED; titrated in office
1.25 mcg — injection
Starting dose for neurogenic ED (e.g., spinal cord injury)
10 mcg — injection
Available as Caverject Impulse prefilled syringe; generic alprostadil vial
20 mcg — injection
Most common strength; available as vial or Caverject Impulse prefilled syringe
40 mcg — injection
Higher strength vial; maximum dose is 60 mcg total per injection
Finding alprostadil injection has been challenging for patients over the past several years. A major 2023 supply disruption by Pfizer — caused by manufacturing capacity being diverted to another essential medication — left many patients unable to access Caverject for extended periods. This was compounded by Pfizer's decision to permanently discontinue the Caverject brand in July 2025.
As of 2026, generic alprostadil injection is available from multiple manufacturers (including Meitheal Pharmaceuticals, which launched in March 2025), but local pharmacy stocking remains inconsistent during the market transition. Alprostadil injection is a specialty drug not carried at every pharmacy — patients are most likely to find it at specialty pharmacies, compounding pharmacies, or through mail-order. Standard retail chains may not stock it or may only carry it at select locations.
To find which pharmacies near you carry alprostadil injection, use medfinder — a service that calls pharmacies on your behalf and texts you results, saving you significant time.
Caverject (alprostadil injection) is not a controlled substance, so it can be prescribed by any licensed prescriber with authority to write prescriptions. However, FDA guidelines require that the first dose be administered in a medical office with medical supervision and dose titration before home self-injection is permitted. In practice, alprostadil injection is most commonly prescribed by specialists.
Urologists — the primary specialists for ED; most experienced with intracavernosal therapy and in-office titration
Men's health clinic providers — specialists in male sexual health and hormonal issues
Primary care physicians (PCPs) — some experienced PCPs prescribe alprostadil injection, particularly for established patients
Endocrinologists — for patients whose ED is associated with hormonal or metabolic conditions
Nurse practitioners and physician assistants — with full prescribing authority in most states, particularly in urology and men's health settings
Some telehealth platforms offer ED consultations, but intracavernosal therapy requires at least one in-person visit for dose titration and injection training before home self-administration is approved.
No. Alprostadil (Caverject) is not a controlled substance under the DEA scheduling system. It is not assigned to any DEA schedule (I through V) and has no recognized potential for abuse or dependence. This means Caverject and generic alprostadil injection can be prescribed by any licensed healthcare provider — including PCPs, urologists, NPs, and PAs — without DEA restrictions.
Prescriptions for alprostadil injection can typically be written for 30-day or 90-day supplies without the refill restrictions that apply to Schedule II–V controlled substances. Insurance prior authorization requirements still apply for many plans, but these are based on medical necessity criteria, not controlled substance regulations.
The most common side effects of Caverject (alprostadil injection) include:
Penile pain (most common, ≥10% in clinical trials; up to 20–40% in real-world use)
Bruising or bleeding at the injection site
Mild dizziness or lightheadedness
Redness or swelling at the injection site
Serious side effects that require immediate medical attention:
Priapism (erection lasting more than 4 hours) — a medical emergency; go to the ER immediately
Penile fibrosis — scarring causing curvature with long-term use; report new curvature to your doctor
Significant hypotension — dizziness, fainting; more common in patients on antihypertensives
Needle breakage — rare; use proper technique and never reuse needles
Know what you need? Skip the search.
Generic Alprostadil Injection
Therapeutically equivalent to Caverject; now available following brand discontinuation in July 2025
Edex
Another FDA-approved alprostadil injection brand by Endo Inc.; available in 10, 20, and 40 mcg doses
Trimix
Compounded combination of alprostadil, papaverine, and phentolamine; often more effective and lower cost per dose than alprostadil monotherapy
Sildenafil (Viagra)
Oral PDE5 inhibitor; first-line oral therapy for ED; widely available as generic at low cost
Tadalafil (Cialis)
Oral PDE5 inhibitor available in daily or as-needed dosing; generic available
Prefer Caverject? We can find it.
Warfarin / Heparin (anticoagulants)
moderateIncreased bleeding risk at injection site; compress site for 5 minutes post-injection
Antihypertensive medications (ACE inhibitors, beta-blockers, calcium channel blockers, alpha-blockers)
moderateAdditive hypotensive effect; monitor blood pressure; start at lowest effective dose
PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil)
majorNot recommended in combination; additive hypotension and increased priapism risk
Other vasoactive intracavernosal agents (papaverine, phentolamine)
majorSignificantly increases risk of prolonged erection and priapism; not recommended without specific prescriber direction
Trazodone / certain antipsychotics
moderateIndependent priapism risk; combined use may further increase priapism risk; discuss with prescriber
Caverject (alprostadil injection) is a highly effective, FDA-approved treatment for erectile dysfunction with over 40 years of clinical use. Over 80% of men in clinical studies achieved erections sufficient for intercourse, and alprostadil works independently of sexual arousal — making it effective even for men with neurogenic or severe vascular ED where oral medications fail. The 2023 shortage and 2025 brand discontinuation were significant challenges for patients, but generic alprostadil is now entering the market and supply should improve over time.
The main challenges in 2026 are cost and local availability. At retail prices historically exceeding $1,000 for a six-vial pack, prior authorization from your insurer is important to pursue. Discount cards (GoodRx, SingleCare) provide meaningful savings, and compounded Trimix may offer a more affordable and even more effective alternative for many men.
If you have a valid prescription and are struggling to find alprostadil injection locally, medfinder can help. Enter your medication, dose, and zip code — medfinder calls pharmacies near you and texts you which ones can fill your prescription. It's the fastest way to find your medication without spending hours on hold.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards